Palvella Therapeutics, Inc. (PVLA) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
PVLA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PVLA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 89.3% | -167.8% | -128.5% |
| 2021 | 92.5% | -165.0% | -145.6% |
Download Data
Export PVLA earnings history in CSV or JSON format
Free sign-in required to download data
Palvella Therapeutics, Inc. (PVLA) Earnings Overview
As of May 8, 2026, Palvella Therapeutics, Inc. (PVLA) reported trailing twelve-month net income of -$49M, reflecting +52.6% year-over-year growth. The company earned $-3.77 per diluted share over the past four quarters.
Looking at the long-term picture, PVLA's historical earnings data spans multiple years. The company achieved its highest annual net income of $19M in fiscal 2023.
Palvella Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$164M net income, -297.1% margin), PRAX (-$327M net income), IMVT (-$464M net income), PVLA has comparable earnings metrics. Compare PVLA vs NKTR →
PVLA Earnings vs Peers
Earnings metrics vs comparable public companies
PVLA Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$42M | -139.3% | -$39M | $-3.71 | - | - |
| 2024 | -$17M | -193.3% | -$14M | $-7.83 | - | - |
| 2023 | $19M | +156.2% | -$12M | $14.74 | - | - |
| 2022 | -$33M | +27.2% | -$43M | $-29.61 | -128.5% | -167.8% |
| 2021 | -$46M | -22.9% | -$52M | $-56.69 | -145.6% | -165.0% |
| 2020 | -$37M | - | -$34M | $-54.67 | -127.0% | -115.7% |
See PVLA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PVLA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PVLA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPVLA — Frequently Asked Questions
Quick answers to the most common questions about buying PVLA stock.
Is PVLA growing earnings?
PVLA EPS is $-3.77, with earnings growth accelerating to +52.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-49M.
What are PVLA's profit margins?
Palvella Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are PVLA's earnings?
PVLA earnings data spans 2020-2025. The accelerating earnings trend is +52.6% YoY. Historical data enables comparison across business cycles.